ХИМИОТЕРАПИЯ ГОРМОНОРЕЗИСТЕНТНОГО РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
https://doi.org/10.17650/1726-9776-2010-6-4-54-60
Аннотация
Об авторах
Я. В. ГридневаРоссия
В. Б. Матвеев
Россия
Б. В. Бухаркин
Россия
Д. З. Купчан
Россия
Список литературы
1. Garmey E., Sartor O., Halabi S.,Vogelzang N. Second-line chemotherapy for advanced hormone-refractory prostatecancer. Clin Advanc Hematol Oncol 2008;6(2):118–32.
2. Berthold D.R., Pond G.R., Soban F. et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer:updated survival in the TAX 327 study. J Clin Oncol 2008;26:242–5.
3. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.
4. Petrylak D.P., Tangen C.M., Hussain M.H.et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.
5. Basch E.M., Somerfield M.R., Beer T.M.et al. American Society of Clinical Oncology endorsement of the Cancer Care OntarioPractice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castrationresistant) prostate cancer. J Clin Oncol 2007;25:5313–8.
6. National Comprehensive Cancer Network.Clinical practice guidelines in oncology:Prostate Cancer2009;2. http://www.nccn.org/professionals/ physi-cian_gls/f_guidelines.asp
7. Poiesz B., Reeves J., McNulty W.et al. Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer. J Clin Oncol 2009;27(Suppl):270;abstr 5145.
8. MacVicar G.R., Greco A., Reeves J. et al. An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrateresistant prostate cancer (CRPC). J Clin Oncol 2009;27(Suppl):249;abstr 5062.
9. Armstrong A.J., Creel P., Turnbull J.et al. A phase I–II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008;14:6270–6.
10. Di Lorenzo G., Figg W.D., Fossa S.D. et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol2008;54:1089–94.
11. Picus J., Halabi S., Rini B. et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006. J Clin Oncol2003;22(Suppl):393;abstr 1578.
12. Ning Y.M., Arlen P.M., Gulley J.L. et al. Phase II trial of thalidomide, bevacizumab, and docetaxel in patients with metastatic castrationrefractory prostate cancer. J Clin Oncol 2008;26(Suppl):250;abstr 5000.
13. Dreicer R., Petrylak D., Agus D. et al. Phase I/II study of bortezomib plus docetaxel in patients with advanced ndrogenindependent prostate cancer. Clin Cancer Res 2007;13:1208–15.
14. Hainsworth J.D., Meluch A.A., Spigel D.R. et al. Weekly docetaxel and bortezomib as first-line treatment for patients with hormonerefractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clin Genitourin Cancer 2007;5:278–83.
15. Ferrero J.M., Chamorey E., Oudard S. et al. Phase II trial evaluating a docetaxelcapecitabine combination as treatment for hormonerefractory prostate cancer. Cancer 2006;107:738–45.
16. Kolodziej M., Neubauer M.A., Rousey S.R. et al. Phase II trial of docetaxel/ capecitabine in hormone-refractory prostate cancer. Clin Genitourin Cancer 2006;5:155–61.17.Vaishampayan U.N., Marur S.,
17. Heilbrun L.K. et al. Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. J Urol 2009;182:317–23.
18. Ross R.W., Beer T.M., Jacobus S. et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.Cancer 2008;112:521–6.
19. Carles J., Font A., Mellado B. et al. Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. Br J Cancer 2007;97:1206–10.
20. Araujo J., Armstrong A.J., Braud E.L. et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086). J Clin Oncol 2009;27(Suppl):249;abstr 5061.
21. Montgomery R.B., Nelson P.S., Lin D. et al. Diethylstilbestrol and docetaxel: a phase II study of tubulin active agents in patients with metastatic, androgenindependent prostate cancer. Cancer 2007;110:996–1002.
22. Beer T.M., Ryan C.W., Venner P.M. et al. Double-blinded randomized study of highdose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25:669–74.
23. Gross M., Higano C., Pantuck A. et al. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007;7:142.
24. Caffo O., Sava T., Comploj E. et al. Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int 2008;102:1080–5.
25. Eymard J.C., Priou F., Zannetti A. et al. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 2007;18:1064–70.
26. Matsumoto A., Inoue A., Yokoi S. et al. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. Int J Urol 2009;16:687–91.
27. Kikuno N., Urakami S., Nakamura S. et al. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 2007;51:1252–8.
28. Oh W.K., Halabi S., Kelly W.K. et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colonystimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003;98:2592–8.
29. Machiels J.P., Mazzeo F., Clausse M. et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008;26:5261–8.
30. Dawson N.A., Halabi S., Ou S.S. et al. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. Clin Genitourin Cancer 2008;6:110–6.
31. Ryan C.W., Stadler W.M., Vogelzang N.J. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormonerefractory prostate cancer. BJU Int 2005;95:963–8.
32. Sinibaldi V.J., Elza-Brown K., Schmidt J. et al. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. Am J Clin Oncol 2006;29:395–8.
33. Salzberg M., Rochlitz C., Morant R. et al. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie 2007;30:355–60.
34. Small E., Demkow T., Gerritsen W.R. et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). In: American Society of Clinical Oncology – Genitourinary Cancers Symposium. February 26–28, 2009, Orlando, FL.
35. Mathew P., Thall P.F., Bucana C.D. et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castrationresistant prostate cancer with bone metastases. Clin Cancer Res 2007;13:5816–24.
36. Tolcher A.W., Chi K., Kuhn J. et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormonerefractory prostate cancer. Clin Cancer Res 2005;11:3854–61.
37. Sternberg C.N., Dumez H., Van P.H. et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 2009;20:1264–9.
38. Chi K.N., Hotte S.J., Yu E.Y. et al. Mature results of a randomized phase II study of OGX- 011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2009;27(Suppl):238;abstr 5012.
39. Chatta G.S., Feinstein T.M., Appleman L.J. et al. Oxaliplatin and docetaxel in castrationresistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: updated results of a phase II trial. J Clin Oncol 2008;26 (Suppl):286;abstr 5148.
40. De Jager R.L., Roman L., Lopatkin N. et al. Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castrationresistant prostate cancer (CRPC). J Clin Oncol 2009;27(Suppl):268;abstr 5140.
41. Morris M.J., Pandit-Taskar N., Stephenson R.D. et al. Phase I/II study of docetaxel and 153Sm for castrate metastatic prostate cancer (CMPC): summary of doseescalation cohorts and first report on the expansion cohort. J Clin Oncol 2009;27(Suppl):248;abstr 5057.
42. Fizazi K., Beuzeboc P., Lumbroso J. et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009;27:2429–35.
43. Cetnar J.P., Rosen M.A., Vaughn D.J. et al. Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2009;27(Suppl);abstr 16055.
44. Zurita A.J., Liu G., Hutson T. et al. Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC). J Clin Oncol 2009;27(Suppl):275; abstr 5166.
45. Dahut W.L., Gulley J.L., Arlen P.M. et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532–9.
46. Pili R., Rosenthal M. AS1404-203 study group investigators. Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study. J Clin Oncol 2008;26(Suppl):251;abstr 5007.
47. Horti J., Widmark A., Stenzl A. et al. A randomized, double-blind, placebocontrolled phase II study of vandetanib plus docetaxel/ prednisolone in patients with hormonerefractory prostate cancer. Cancer Biother Radiopharm 2009;24:175–80.
48. Tester W., Ackler J., Tijani L. et al. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. Cancer J 2006;12:299–304.
49. Cumashi A., Tinari N., Rossi C. et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008;270:229–33.
50. Guerin O., Formento P., Lo Nigro C. et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 2008;134:51–7.
51. Michaelson M.D., Regan M.M., Oh W.K. et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009;20:913–20.
52. Park S.I., Zhang J., Phillips K.A. et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68:3323–33.
53. Vandyke K., Dewar A.L., Farrugia A.N. et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009;23:994–7.
54. Koreckij T., Nguyen H., Brown L.G. et al. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009;101:263–8.
55. Lin A.M., Rini B.I., Derynck M.K. et al. A phase I trial of docetax-el/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer 2007;5:323–8.
56. Sonpavde G., Periman P.O., Bernold D. et al. Sunitinib malate for metastatic castrationresistant prostate cancer following docetaxelbased chemotherapy. Ann Oncol 2010;21:319–24.
57. McDonnell T.J., Troncoso P., Brisbay S.M. et al. Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgenindependent prostate cancer. Cancer Res 1992;52:6940–4.
58. Gleave M.E., Miayake H., Goldie J. et al. Targeting Bcl-2 gene to delay androgenindependent progression and enhance chemosensitivity in prostate cancer using antisense Bcl-2 oligodeoxynucleotides. Urology 1999;54:36–46.
59. Leonetti C., Biroccio A., D’Angelo C. et al. Therapeutic integration of c-myc and Bcl-2 antisense molecules with docetaxel in a preclinical model of hormonerefractory prostate cancer. Prostate 2007;67:1475–85.
60. Liu G., Kelly W.K., Wilding G. et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrateresistant prostate cancer. Clin Cancer Res 2009;15:3172–6.
61. Sowery R.D., Hadaschik B.A., So A.I. et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC- 3 cells to chemotherapy. BJU Int 2008;102:389–97.
62. Kattan J.G., Farhat F.S., Chahine G.Y. et al. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). Invest New Drugs 2008;26:75–9.
63. Fizazi K., Le M.A., Hudes G. et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007;8:994–1000.
64. Trivedi C., Redman B., Flaherty L.E. et al. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 2000;89:431–6.
65. Abratt R.P., Brune D., Dimopoulos M.A. et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 2004;15:1613–21.
66. Silva E., Silva F. Phase II study of intravenous vinorelbine plus hormone therapy in hormone-refractory prostate cancer. J Clin Oncol 2006;24(1):18;abstr 14601.
67. Nakabayashi M., Ling J., Xie W. et al. Response to Vinorelbine with or without Estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J 2007;13:125–9.
68. Sewak S., Kosmider S., Ganju V. et al. A phase II study of paclitaxel and vinorelbine (Pac-Vin) in hormone-refractory metastatic prostate cancer (HRPC): a final update. J Clin Oncol 2007;25(1):18;abstr 15505.
69. Sewak S., Kosmider S., Ganju V. et al. Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting. Intern Med J 2010;40:201–8.
70. Carducci M.A., Padley R.J., Breul J. et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679–89.
71. Carducci M.A., Saad F., Abrahamsson P.A. et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormonerefractory prostate cancer. Cancer 2007;110:1959–66.
72. Nelson J.B., Love W., Chin J.L. et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008;113:2478–87.
73. James N.D., Caty A., Borre M. et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009;55:1112–23.
Рецензия
Для цитирования:
Гриднева Я.В., Матвеев В.Б., Бухаркин Б.В., Купчан Д.З. ХИМИОТЕРАПИЯ ГОРМОНОРЕЗИСТЕНТНОГО РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ. Онкоурология. 2010;6(4):54-60. https://doi.org/10.17650/1726-9776-2010-6-4-54-60
For citation:
Gridneva Ya.V., Matveev V.B., Bukharkin B.V., Kupchan D.Z. CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCER. Cancer Urology. 2010;6(4):54-60. (In Russ.) https://doi.org/10.17650/1726-9776-2010-6-4-54-60